Varicella Virus Vaccine Market

Published on 2025-11-08
Report Code: 453
170-350 pages

Varicella Virus Vaccine Market Segments: By Vaccine (Monovalent Varicella Vaccine and Combination Varicella Vaccine); By Application (Chickenpox Immunization, Herpes Zoster Immunization and MMRV Immunization); and Region - Global Analysis of Market Size, Share & Trends for 2014 - 2020 and Forecasts to 2030

Buy Now

Add to cart

Table Of Content

1. Executive Summary

2. Global Varicella Virus Vaccine Market

2.1. Product Overview

2.2. Market Definition

2.3. Segmentation

2.4. Assumptions and Acronyms

3. Research Methodology

3.1. Research Objectives

3.2. Primary Research

3.3. Secondary Research

3.4. Forecast Model

3.5. Market Size Estimation

4. Average Pricing Analysis

5. Macro-Economic Indicators

6. Market Dynamics

6.1. Growth Drivers

6.2. Restraints

6.3. Opportunity

6.4. Trends

7. Correlation & Regression Analysis

7.1. Correlation Matrix

7.2. Regression Matrix

8. Recent Development, Policies & Regulatory Landscape

9. Risk Analysis

9.1. Demand Risk Analysis

9.2. Supply Risk Analysis

10. Global Varicella Virus Vaccine Market Analysis

10.1. Porters Five Forces

10.1.1. Threat of New Entrants

10.1.2. Bargaining Power of Suppliers

10.1.3. Threat of Substitutes

10.1.4. Rivalry

10.2. PEST Analysis

10.2.1. Political

10.2.2. Economic

10.2.3. Social

10.2.4. Technological

11. Global Varicella Virus Vaccine Market

11.1. Market Size & forecast, 2020A-2030F

11.1.1. By Value (USD Billion) 2020-2030F; Y-o-Y Growth (%) 2021-2030F

11.1.2. By Volume (Billion Units) 2020-2030F; Y-o-Y Growth (%) 2021-2030F

12. Global Varicella Virus Vaccine Market: Market Segmentation

12.1. By Regions

12.1.1. North America:(the U.S. and Canada), By Value (USD Billion) 2020-2030F; Y-o-Y Growth (%) 2021-2030F

12.1.2. Latin America: (Brazil, Mexico, Argentina, Rest of Latin America), By Value (USD Billion) 2020-2030F; Y-o-Y Growth (%) 2021-2030F

12.1.3. Europe: (Germany, UK, France, Italy, Spain, BENELUX, NORDIC, Hungary, Poland, Turkey, Russia, Rest of Europe), By Value (USD Billion) 2020-2030F; Y-o-Y Growth (%) 2021-2030F

12.1.4. Asia-Pacific: (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia Pacific), By Value (USD Billion) 2020-2030F; Y-o-Y Growth (%) 2021-2030F

12.1.5. the Middle East and Africa: (Israel, GCC, North Africa, South Africa, Rest of the Middle East and Africa), By Value (USD Billion) 2020-2030F; Y-o-Y Growth (%) 2021-2030F

12.2. By Vaccine: Market Share (2020-2030F)

12.2.1. Monovalent Varicella Vaccine, By Value (USD Billion) 2020-2030F; Y-o-Y Growth (%) 2021-2030F

12.2.2. Combination Varicella Vaccine, By Value (USD Billion) 2020-2030F; Y-o-Y Growth (%) 2021-2030F

12.3. By Application: Market Share (2020-2030F)

12.3.1. Chickenpox Immunization, By Value (USD Billion) 2020-2030F; Y-o-Y Growth (%) 2021-2030F

12.3.2. Herpes Zoster Immunization, By Value (USD Billion) 2020-2030F; Y-o-Y Growth (%) 2021-2030F

12.3.3. MMRV Immunization, By Value (USD Billion) 2020-2030F; Y-o-Y Growth (%) 2021-2030F

13. Company Profile

14. GlaxoSmithKline PLC

14.1. Company Overview

14.2. Company Total Revenue (Financials)

14.3. Market Potential

14.4. Global Presence

14.5. Key Performance Indicators

14.6. SWOT Analysis

14.7. Product Launch

15. Merck & Co. Inc.

16. GC Pharma (Green Cross Holdings)

17. Bio-Med Pvt Ltd

18. Novo Medi Sciences Pvt Ltd

19. Sanofi

20. Takeda Pharmaceutical Company Limited

21. Mitsubishi Tanabe Pharma Corporation.

22. Emcure Pharmaceuticals Limited

23. Other Prominent Players

Consultant Recommendation

The above-given segmentations and companies could be subjected to further modification based on in-depth feasibility studies conducted for the final deliverable